Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Repo...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A817460110

Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401

Full title

Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401

Publisher

Intellisphere, LLC

Journal title

Neurology Live, 2024

Language

English

Formats

Publisher

Intellisphere, LLC

Subjects and topics

Full title

Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401

Record Identifier

TN_cdi_gale_infotracmisc_A817460110

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A817460110

ISSN

2767-4258

Log in as a Library member

Celebrating and sharing stories of Indigenous Australia, and helping to locate and prioritise Indigenous voices in the Library's collections.

Learning programs and resources linked to the curriculum.

Showcasing people, places and ideas inspired by the collection and the library community.